A clinical feature of hyperlipidemia in patients with central diabetes insipidus
- PMID: 11200935
- DOI: 10.1507/endocrj.47.557
A clinical feature of hyperlipidemia in patients with central diabetes insipidus
Abstract
In this study, we analyzed plasma lipid and lipoprotein levels before and after treatment with 1-desamino-8-D-arginine vasopressin (DDAVP) in subjects with partial and complete central diabetes insipidus (DI) in order to determine how a shortage and supplement of this hormone affect plasma lipid metabolism. The subjects consisted of 6 patients with partial and 6 with complete central DI. After treatment with DDAVP through nasal cavity, plasma total cholesterol (TC) level did not decrease either in complete or partial form. Plasma triglyceride (TG) levels decreased from 306+/-175 mg/dl to 198+/-91 (35% decrease, p=0.027) in complete form, while TG did not change significantly in partial form. A detailed investigation of plasma lipoprotein metabolism during treatment with DDAVP was carried out in 3 of the 6 subjects with complete form of DI. Lipoprotein lipase activity and mass in post-heparin plasma from those three subjects tended to increase after treatment with DDAVP, along with the complete disappearance of an unusual lipoprotein between low density lipoprotein (LDL) and very low density lipoprotein (VLDL) as analyzed by polyacrylamide gel electrophoresis. These results suggest that the DDAVP treatment has a favorable effect on lipid and lipoprotein metabolism, especially triglyceride-rich lipoproteins, either directly or through modifying factors contributing to lipid metabolism.
Similar articles
-
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.Clin Pharmacol Ther. 2003 Sep;74(3):236-44. doi: 10.1016/S0009-9236(03)00170-X. Clin Pharmacol Ther. 2003. PMID: 12966367 Clinical Trial.
-
Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.Atherosclerosis. 1997 Jun;131(2):229-36. doi: 10.1016/s0021-9150(97)00054-3. Atherosclerosis. 1997. PMID: 9199276
-
High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction--effects of treatment.Q J Med. 1986 May;59(229):513-21. Q J Med. 1986. PMID: 3763814
-
Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition.Atherosclerosis. 1995 Oct;117(2):253-61. doi: 10.1016/0021-9150(95)05580-p. Atherosclerosis. 1995. PMID: 8801871
-
Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.Atherosclerosis. 2001 Mar;155(1):251-60. doi: 10.1016/s0021-9150(00)00634-1. Atherosclerosis. 2001. PMID: 11223449 Clinical Trial.
Cited by
-
Modern approach in treatment of diabetes insipidus.Bosn J Basic Med Sci. 2005 May;5(2):38-42. doi: 10.17305/bjbms.2005.3282. Bosn J Basic Med Sci. 2005. PMID: 16053453 Free PMC article. Review.
-
Increased copeptin may reflect vasopressin-related metabolic changes after bariatric surgery.Obesity (Silver Spring). 2025 Feb;33(2):298-307. doi: 10.1002/oby.24200. Epub 2024 Dec 26. Obesity (Silver Spring). 2025. PMID: 39725569 Free PMC article.
-
The Impact of Hydration on Metabolic Outcomes: From Arginine-Vasopressin Signaling to Clinical Implications.Medicina (Kaunas). 2025 May 1;61(5):838. doi: 10.3390/medicina61050838. Medicina (Kaunas). 2025. PMID: 40428796 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous